ALPS ADVISORS INC

Position in APLS — Apellis Pharmaceuticals, Inc.

CIK 1376113 Denver, CO

Position in APLS

as of Mar 31, 2026 · filed May 8, 2026 Compact

Position Value

$4,186,253

+$1,581,410 QoQ

Shares Held

104,058

+0.3% QoQ

Ownership

0.081%

of shares outstanding

% of Portfolio

0.02%

of 13F equity value

Holder Rank

#102

of 320 holders

Holding Since

Mar 2020

11 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

ALPS ADVISORS INC holds $156,743,120 across 93 Biotechnology names. APLS ranks #6 (2.7% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	RPRX	Royalty Pharma plc	496,682	$23,825,835
2	KYMR	Kymera Therapeutics, Inc.	66,457	$5,535,203
3	CGON	CG Oncology, Inc.	68,737	$4,652,120
4	MIRM	Mirum Pharmaceuticals, Inc.	49,128	$4,538,444
5	CELC	Celcuity Inc.	37,663	$4,298,854
6	APLS	Apellis Pharmaceuticals, Inc. This page	104,058	$4,186,253
7	XENE	Xenon Pharmaceuticals Inc.	67,723	$3,938,092
8	APGE	Apogee Therapeutics, Inc.	45,586	$3,836,973

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$4,186,253	104,058	+0.3%	Shares	Defined	2026-05-08
2025-12-31	$2,604,843	103,696	+65.1%	Shares	Defined	2026-02-12
2025-09-30	$1,421,503	62,815	-7.3%	Shares	Defined	2025-11-05
2025-06-30	$1,172,942	67,761	-36.5%	Shares	Defined	2025-08-11
2021-09-30	$3,514,590	106,632	+1.0%	Shares	Defined	2021-11-15
2021-06-30	$6,675,436	105,624	-22.9%	Shares	Defined	2021-08-11
2021-03-31	$5,879,485	137,019	+0.3%	Shares	Defined	2021-05-07
2020-12-31	$7,816,608	136,654	+41.7%	Shares	Defined	2021-02-03
2020-09-30	$2,908,840	96,415	-6.4%	Shares	Defined	2020-11-05
2020-06-30	$3,364,404	103,013	-22.8%	Shares	Defined	2020-08-05
2020-03-31	$3,576,947	133,518	—	Shares	Defined	2020-05-06
No filing history on record for this holder in this stock.